Search for content, post, videos

Spago Nanomedical receives go-ahead to include patients with pancreatic cancer

Mats Hansen SpagoPix

Spago Nanomedical has received approval from the Swedish Medical Products Agency to initiate recruitment of patients with pancreatic cancer for the clinical study with the contrast agent SN132D.

”By including another patient group, we can in a cost-effective way demonstrate a broader use of SN132D and build additional value in the SpagoPix project at an early clinical development stage,” says CEO Mats Hansen.

The SPAGOPIX-01 study

The SPAGOPIX-01 study is carried out at Sahlgrenska University Hospital in Gothenburg and the University Hospital in Uppsala. The recruitment of patients with suspected or confirmed pancreatic cancer with spread to the liver begins immediately.

SN132D is a manganese-based nanomedical contrast agent with the potential to improve the precision of cancer diagnostics with magnetic resonance imaging (MRI) and increase the efficiency of the healthcare system. Interim data from the SPAGOPIX-01 study have shown that SN132D provides clinically relevant and selective contrast enhancement in breast cancer tumors with minimal background contrast and good safety.